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Recently, we and others have characterized the HIV-sup-
pressive activity of human β-defensins (hBD) 1–3. Our
mechanistic studies indicate that hBD2 inhibits HIV
through two distinct mechanisms. The first mechanism
results in lower HIV infectivity. The second mechanism is
intracellular, since it is observed even delaying treatment
up to 2 hours after infection, which is not consistent with
a mode of inhibition based on entry-fusion events. We
hypothesized that this second antiviral mechanism is due
to changes in the intracellular environment, possibly
mediated by a cellular receptor. Treatment of cells in
infectivity assays with an antibody specific for CCR6, a
chemokine receptor that also functions as a receptor for
hBD2, abrogated HIV inhibition by this defensin. Further,
treatment of HIV-1 infectivity assays with MIP-3α, the
cognate ligand for CCR6, resulted in inhibition of infec-
tion. Finally, single-cycle HIV infection is inhibited in
cells that express CCR6 following transfection with an
expression construct, but not in their CCR6low counter-
part. Experiments performed using HIV pseudotyped with
AMLV envelope showed that inhibition by hBD2 of HIV
replication is sensitive to treatment with the Gi protein
inhibitor pertussis toxin.CCR6 is an important receptor in
the context of mucosal immunity, as it is expressed in
CD4+CD45+CCR5+ lymphocytes, which are highly sus-
ceptible to HIV infection, and on dendritic cells, which are
thought to play a crucial role in early events in HIV trans-
mission. Therefore, an HIV suppressive mechanism target-
ing CCR6 is likely to play an important role in mucosal
immunity to HIV.
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